According to the announcement by Tibet Weixinkang (603676.SH), its wholly-owned subsidiary Tibet Zhongwei Chengkang Pharmaceuticals Co., Ltd. ("Zhongwei Chengkang" or "licensee") signed an exclusive license agreement with AFT Pharmaceuticals Limited ("AFT") on September 27, 2024. Under the agreement, AFT granted Zhongwei Chengkang an exclusive license to develop, sell, and commercialize paracetamol ibuprofen injection applicable for indications (including but not limited to pediatric indications) in the licensed territory (Mainland China).

According to the agreement, Zhongwei Chengkang will pay AFT exclusive license fees and royalties. The maximum exclusive license fee is up to 1.25 million USD, including the first milestone payment, development milestone payments, sales milestone payments; the royalty fee shall not exceed 10% of the net sales of the product within patent rights.

The authorized product under the agreement is a non-opioid intravenous analgesic paracetamol ibuprofen injection, designed specifically for postoperative pain management. It is clinically approved for the relief of mild to moderate pain in adults and as an adjuvant analgesic therapy alongside opioid analgesics for moderate to severe pain. Controlled trial data conducted in the USA indicate that the paracetamol ibuprofen injection has a faster onset of action compared to ibuprofen injection, paracetamol injection, and placebo, with superior analgesic effects and comparable safety; it can reduce the use of opioid medications as part of postoperative multimodal pain management. Currently, there have been no applications or listings domestically.